OKADAI BIOBANK 岡大バイオバンク
menu
お知らせ

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

このお知らせには詳しい内容はありません